So if this passes the MI House, we'd see prices set by the same ham-handed government that gave us COVID mandates? 

Call your state reps, everybody. If you need contact info, check out the Toolbox in the pinned post.

An opinion in favor:

https://www.bridgemi.com/guest-commentary/opinion-michigan-needs-state-drug-board-combat-rising-prices-greed

Opinion | Michigan needs state drug board to combat rising prices, greed
By Michigan State Senator Kristen McDonald Rivet, a Democrat who represents Michigan Senate District 35 which includes Bay City, Midland, Saginaw and surrounding townships in the Great Lakes Bay Region

October 19, 2023

The rising cost of prescription drugs is a crisis for Michigan families. Democrats at the state and federal levels have been working hard to tackle this issue head-on and hold big drug companies accountable.

As elected leaders, we often hear from constituents that prescription drug prices are an urgent matter that needs to be addressed, and I wholeheartedly agree. The Michigan Prescription Drug Task Force found nearly a third of residents aged 19-64 stopped taking their prescriptions because of cost.

In Michigan, we saw the cost of 500 prescription drugs rise at twice the rate of inflation during the pandemic in 2020. During a time when we’ve seen the cost of groceries and other essentials rise, the price of many prescription drugs continued to skyrocket well beyond the rate of inflation. The corporate greed by drug companies at the expense of our health and livelihoods must stop.

This is not acceptable.

Families should not have to pick between buying groceries or paying for their life-saving medication. Patients should not end up in an emergency room because they cannot afford the necessary prescriptions to manage their health conditions.

Scientific advancement has brought us so many prescription drugs that help people achieve a better quality of life. It is shameful and upsetting that these game-changing medicines remain out of reach to many because of high prices, outrageous profits and plain corporate greed.

In Michigan, we have made some strides to bring transparency to drug pricing and rein in costs. We all know there is more work to be done.

That is why I have introduced legislation as part of a package (Senate Bills 483, 484, and 485), which will create the Prescription Drug Affordability Board and ensure it is made up of nonpartisan leaders in health care economics, health policy, and clinical medicine with no personal or financial stake in the pharmaceutical industry.

There will be strict rules to prevent politicians, Big Pharma, and health care industry or special interest groups from influencing the board’s decisions.

A truly independent board is what makes this work.

We have seen recent progress at the federal level. The 2022 Inflation Reduction Act allows Medicare to negotiate prices on certain high-cost prescription drugs like insulin for seniors.

This policy marks a major win for consumers. I was disappointed, though not surprised, when the U.S. Chamber of Commerce and drug companies Merck and Bristol Myers Squibb filed lawsuits to block this law to protect industry profits over people.

The Medicare prescription negotiation program would rein in out-of-control drug prices and allow these medications to serve their purpose by getting into the hands of more Americans who need them to live and thrive.

While I am confident the law will stand up in court, these lawsuits serve as yet another reminder of the need to hold pharmaceutical companies accountable.

As the Legislature is in session this fall, advancing the PDAB legislative package that will rein in the rising cost of prescription drugs will be one of my top priorities. In the meantime, I welcome citizens struggling with the high price of prescription drugs to contact my office and share your stories.

Working together, we can tackle this critical issue and bring relief to the Michiganders struggling to keep up with the rising cost of their medicine.

Try as I might, cannot find the words "supply" or "competition" in this opinion.  Fairly quickly, the government will allocate an ever shrinking supply of critical drugs.

Be prepared to demonstrate your intersectionality to the Michigan Ministry of DEI when you need pharmaceuticals in the future.

Another opinion in favor, also from BridgeMI:

https://www.bridgemi.com/guest-commentary/opinion-michigan-doctors-support-state-drug-panel-ignore-big-pharma-ads

Michigan doctors support state drug panel, ignore Big Pharma ads
Dr. Aisha Harris - October 30, 2023

Across Michigan, physicians work hard to help our patients get access to the care they need – and that includes supporting legislation that can reduce the astronomical cost of prescription drugs. That’s why many of us are voicing our support for legislation that would establish a Prescription Drug Affordability Board (PDAB) in Michigan.

As advocates for our patients, doctors support Senate Bills 483 - 485 to create the PDAB, because this independent board, made up of nonpartisan experts in health care, can help rein in runaway prescription drug costs. Using data, this panel can set limits on the most expensive drugs, making medications more affordable for countless Michigan families.

Unfortunately, Big Pharma and its army of high-priced Michigan lobbyists are actively misleading people and even trying to fool families and legislators by explicitly representing themselves as physicians who oppose the PDAB.

Yes, you read that right.

Big Pharma, tapping its massive billion-dollar ad budgets, is using paid advertisements and websites to mislead people into thinking doctors don’t support an independent board designed to cap prescription drug costs, make them more affordable and hold drug corporations accountable for gouging our patients.

We wish to be clear. Doctors want our patients to get access to affordable medications. In Michigan, doctors support the PDAB. The Michigan State Medical Society supports PDAB. The Michigan Chapter of the American College of Physicians supports the PDAB. So do the AARP, the NAACP and many other organizations that advocate for families.

Here’s who doesn’t support Michigan’s PDAB: Large drug companies.

During hearings in September, every organization that testified against PDAB was either funded by or linked closely to pharmaceutical companies, including the National Organization for Rare Diseases and the Michigan Society of Hematology and Oncology (MSHO), whose website shows a long list of “elite” corporate sponsors that include drug giants Merck, Amgen, Abbvie, Pfizer and many more.

In 2022, Pfizer pulled in more than $100 billion in revenue; Johnson & Johnson, more than $94 billion. Merck has raked in $49.9 billion with a single drug, diabetes medication Januvia, since it launched without competition 17 years ago. Merck’s CEO Robert Davis was paid a handsome $13.72 million.

This summer, Amgen announced that it hauled in $7 billion for the quarter – more than $559 million over last year – even as patients must pay thousands of dollars for lifesaving drugs like cancer medication Enbrel, which has gone up in cost by 346 percent since 2008.

As a physician, I can say with certainty that a drug is not 346 percent more effective just because it’s 346 percent more expensive.

Meanwhile, my patients and countless more across Michigan can’t afford their life saving medications. Michiganders’ wages went up 11 percent between 2012 and 2017, yet drug costs increased by nearly 60 percent. Patients and families are constantly getting left behind, even as drug companies continue to pad their profits. Our patients are the ones who suffer.

Physicians all too often see our patients make the hard choices between paying for heat in winter or the asthma medication they need to breathe. We care for patients who were forced to ration their diabetes medication or insulin, which can cost hundreds of dollars out of pocket, putting them at risk of experiencing diabetic ketoacidosis, which can be fatal if untreated.

Michigan’s PDAB is a crucial step toward reining in out-of-control drug costs. With a robust PDAB that can keep costs in check and hold drug companies accountable when they try to gouge families, Michigan can help more people get access to affordable medications. Michigan doctors support PDAB because we took an oath to put our patients’ health and wellbeing first, unlike profit-driven drug companies.

Dr. Aisha Harris is a family physician in Flint at Harris Family Health, a direct primary care clinic. She graduated from Georgetown University School of Medicine and completed her family medicine residency at the University of Illinois in Chicago.

Still no mention of the words "supply" or "competition" in this second PDAB opinion.  The fact that Big Pharma is rapacious and incompetent does not assure any level of government competence in drug pricing and distribution.

Another significant gap: proof of effectiveness.

Commissions litter the American landscape at every level of government.

If any commission, anywhere, had ever sustainably cut drug prices, surely these bill advocates would be shouting the evidence from the rooftops.

Crickets.

These three Michigan Senate bills have been idling in the House Insurance and Financial Services Committee since October 4, 2023.  Chairwoman Brenda Carter may be getting ready to move them.  Naomi Lopez, an adjunct scholar at the Mackinac Center for Public Policy, has some insights:

https://www.bridgemi.com/guest-commentary/opinion-who-should-control-michigans-medicine-cabinet

Opinion | Who should control Michigan’s medicine cabinet?
By Naomi Lopez - June 10, 2024

In an effort to “do something” about prescription drug prices, some Michigan lawmakers want to copy an initiative passed in several states, most notably Colorado. The proposed Prescription Drug Affordability Board would set price caps on medications it deems too expensive. Before Michigan lawmakers import this misguided policy, they should consider whether they want an unaccountable board to control the state’s medicine cabinet.

The potential ramifications of handing over decisions about access to prescription medicines to a new unelected state board are huge. Similar proposals were recently vetoed in Virginia. And it failed four times in the Wisconsin Legislature, including getting voted down again last month. Before Michigan follows in Colorado’s footsteps, the public should be asking lawmakers five important questions.

1. Why are advocates for patients with rare diseases, who are often most impacted by drug pricing decisions, excluded from the board’s represented members? The proposal requires a patient advocate but the patient groups often facing the cruelest diseases and fewest treatment options are left without a voice.

2. Why does Michigan’s proposed law not ban the use of “quality-adjusted life years,” a controversial metric that devalues the lives of the elderly, those with physical and mental disabilities, and chronic conditions? The use of this measure has already been outlawed in the federal Medicare program and should not be allowed here. Michigan lawmakers must ensure that they don’t hard code discriminatory treatment against the most vulnerable patients in creating this board.

3. Who will get the “savings” the board is tasked to create? There are no guarantees or provisions that any savings achieved through price caps and restrictions will be passed on to consumers. The result could be zero financial relief for patients with access to fewer treatment options.

4. What is the recourse for vulnerable patients subject to the board’s decisions? Colorado has targeted a popular arthritis medication for potential price controls and restrictions. According to Michigan's own health data, arthritis is more prevalent in the state than the national average. In addition, the disease burden of arthritis can also affect the ability to work, may disproportionately affect those in the manual trades and affect those who are older. The repercussions of ceding authority over important health care decisions to an unelected and unaccountable board will be far-reaching.

5. Will Michigan lawmakers themselves be subject to this board? Lawmakers serving in the Michigan House may participate in a state-sponsored plan that is governed by federal law. As proposed, this health plan would be exempt from a prescription board’s decisions. Before Michigan lawmakers hand over power and authority for critical health care decisions, they should be willing to operate by the same set of rules and consequences that they would impose on their constituents.

While the interest to reduce drug prices is commendable, a willingness to move forward without protecting patient access to treatments and with no accountability to citizens is a perilous prescription. Programs cannot be evaluated by their intentions. Outcomes matter and they matter even more so where patient well-being is concerned. Michigan’s lawmakers should learn from others’ mistakes and dangerous examples, not double down on them.

Outstanding article, and great action items!

The Michigan Senate revived the Prescription Drug Affordability Board concept, this time with a Republican's support:

https://www.bridgemi.com/michigan-government/prescription-price-cap-plan-passes-michigan-senate-dems-decry-exploitation

Prescription price cap plan passes Michigan Senate as Dems decry ‘exploitation’
By Simon D. Schuster - April 24, 2025

*   Michigan’s Democratic-led Senate approves plan to create Prescription Drug Affordability Board
*   Board could cap prescription prices if members determine costs are preventing patients from receiving deeded care
*   Pharmaceutical industry and most Republicans oppose plan, which one lawmaker calls a ‘Soviet-style price-fixing scheme’

Michigan Democrats are taking another stab at creating a government board intended to rein in prescription drug costs, this time with slightly more Republican support but an uncertain path forward in the GOP-controlled House.

Bills that could empower state government to cap prices on expensive prescription drugs cleared the Michigan Senate on Thursday, with one Republican joining majority Democrats to support the creation of a Prescription Drug Affordability Board.

Democrats have pushed the measure as a means of directly lowering the cost of expensive medications. Many Republicans, however, have criticized it as an unproven means of meddling in a free market better left untouched.

“This board is not about stifling innovation. It's about stopping exploitation that is happening now,” said Sen. Sue Shink, D-Northfield Township.

The legislation would create a five-member board and a separate 21-member council that could review prescription drugs for cost and affordability, and set caps on their cost if they determine the cost of the medication is preventing patients from receiving the treatment they need.

Private insurers and Medicaid would have to comply with the limits set by the board, which would be appointed by the governor and receive recommendations from a council of stakeholders.

The pharmaceutical sector remains strongly opposed, with one industry group calling the proposed board “a disaster for patients.”

The legislation would give “unelected bureaucrats a veto pen over the medicine or the treatments doctors prescribe and patients need,” Stami Turk, the Director of Public Affairs for PhRMA, said in a statement.

Senate Minority Leader Aric Nesbitt, R-Porter Township, called it a “Soviet-style price-fixing scheme” and a “bureaucratic boondoggle” that hasn’t worked in other states.

But supporters see the proposal as an urgently-needed intervention amid rising healthcare costs.

Michiganders “are rationing their medication, skipping doses or going without it altogether” due to high costs, said Sen. Darrin Camilleri, D-Brownstown Township.

Minnesota, Colorado, Washington and Maryland have created similar boards with prescription drug price-setting powers. A 2024 review of their boards in the journal Health Affairs found the long-term impacts of those price controls “on benefit design, patient access and innovation are not yet known.”

Gov. Gretchen Whitmer first called for the creation of a Prescription Drug Affordability Board in an August 2023 speech, and lawmakers introduced a proposal soon after. But the legislation failed to gain traction in the Legislature when Democrats controlled both chambers.

The prior version of the proposal passed the Senate in October 2023 along party lines. Democratic House members said they had “no explanation” why the House never took up the legislation when their party controlled the chamber. Now, however, Republicans control the House.

“Last time, I was persuaded by the idea that the market should determine the cost of (prescription drugs),” said Sen. John Damoose of Harbor Springs, the lone Republican supporter for the package.

“The more I learned, the more apparent it became that calling the prescription drug market a free market is a total farce.”

Getting the GOP majority in the House to come around appears to be an uphill battle. Democratic legislators in the House said they have yet to convince any Republicans to come forward to support the bills, but have only begun to try.

Speaking with reporters Thursday, House Speaker Matt Hall, R-Richland Township, called it a “very controversial proposal.”

While Hall said he “supported bipartisan solutions” for lowering drug costs, he referred the Senate package to the Government Operations Committee, a panel where legislation is often sent to die.

“I think that if Republicans in the House are smart, they will make this bipartisan and negate this as a talking point in the next election cycle,” said Rob Davidson, an emergency physician from West Michigan and former Democratic congressional candidate who supports the legislation.

Morning Brew, a left-leaning daily e-news source, brings practical skepticism to its overview of state UPLs (upper price limits).

https://www.healthcare-brew.com/stories/2025/04/16/state-drug-pricing-boards-gaining-momentum

State drug-pricing boards are gaining momentum

Experts say more states may follow after judge dismisses Amgen lawsuit.

April 21, 2025

Now that the US government is negotiating drug prices directly with manufacturers, states want to get in on the action, too.

These efforts vary by state, but generally involve creating a board to review drugs’ affordability and sometimes setting upper price limits (UPLs). While none have implemented UPLs as of April, as the idea gains momentum, there are questions about UPLs and boards’ legality, practicality, and whether they will actually lower costs for patients.

A legal first

Colorado, for instance, enacted legislation to establish a prescription drug board in 2021, and drug prices have continued to rise since then. Over the last year, that board reviewed five drugs and declared three unaffordable, including biopharmaceutical company Amgen’s Enbrel, a biologic which treats autoimmune disorders like rheumatoid arthritis. The state then moved to set a UPL for “all purchases and payer reimbursements” in February 2024.

Enbrel can cost about $8,000 a month without insurance, according to GoodRx, and cost insurers in Colorado $46,772 per patient in 2022, according to the Colorado All Payer Claims Database—though Amgen advertises a co-pay program promising insured patients can pay “as little as $0 out-of-pocket for each dose.”

Amgen responded by suing the state in March 2024—the first legal challenge to this broader concept—alleging this move was unconstitutional. On March 28, a judge ruled that the company lacked standing and threw the case out, creating a path for Colorado to continue with its board.

Amgen moved to appeal the ruling in early April.

“We continue to have significant concerns with the board’s flawed policy and procedures during the rulemaking process to set an upper payment limit…Price controls will not meaningfully address affordability at the pharmacy counter and will instead create new access barriers for patients,” Amgen spokesperson Kelley Davenport said in an emailed statement to Healthcare Brew.

The Colorado Division of Insurance, which oversees the board, did not respond to a request for comment, but Isabel Cruz, policy director at the Colorado Consumer Health Initiative, sent a statement to Stat News celebrating the ruling as a promising step forward.

“Drugs don’t work if people cannot afford them,” she wrote.

Unanswered questions

Zachary Cook, VP of Healthcare Policy for government affairs consulting firm Stateside Associates, told Healthcare Brew via email he expects the ruling could inspire other states to create boards of their own.

Starting with Maryland in 2019, at least nine states have implemented prescription drug affordability review initiatives, including boards, according to a 2024 blog post from the National Alliance of State Pharmacy Associations. States like Michigan are debating implementing drug affordability reviews.

Colorado’s review board is set to start Enbrel rulemaking during a May 23 meeting.

This concept has inspired mixed reactions and plenty of questions. Patient advocacy organizations like the American Cancer Society Action Network (ACS CAN) and the Cystic Fibrosis Foundation have said that boards could potentially help drive down costs, but have the potential to hurt patient access if they do not center patients in the design process.

For instance, if manufacturers think a new drug could be subject to a UPL, they might jack up launch prices to compensate, ACS CAN said in a recent report. Manufacturers could also choose to stop selling a drug in a state with a low UPL or eliminate patient assistance programs to make up for lost profits.

“The impact of UPLs could be positive, negative, or a mix of both, depending on how they are implemented,” the report read.

Cook echoed this idea.

“There are many unknowns as to the effects of a board-implemented UPL on drug cost and patient access,” Cook said.

Michael Abrams, a managing partner at healthcare consulting firm Numerof & Associates, told us he agreed the approach raises questions. (He disclosed his company has worked with Amgen in the past but does not currently.)

“As more and more states set upper price limits on more and more individual drugs, it becomes a huge administrative burden, both for the state and for the pharmaceutical companies, and that simply adds to everybody’s overhead,” he said.

He added that many patients don’t pay the list price, and it’s unclear whether UPLs will actually result in lower costs for consumers.

“This general approach just doesn’t seem to be viable,” he said.

Caroline Catherman joined Healthcare Brew in July 2024 after three years as a health reporter for the Orlando Sentinel. Her work has appeared in outlets including CNN, Science Magazine, and The Chicago Tribune. She holds a master’s in health, environment, and science journalism from Northwestern University and degrees in psychology and English from Emory University, where she was first author on a public health study.